Journal
ANNALS OF INTENSIVE CARE
Volume 1, Issue -, Pages -Publisher
SPRINGER HEIDELBERG
DOI: 10.1186/2110-5820-1-3
Keywords
-
Categories
Funding
- National Health and Medical Research Council/Victorian Neurotrauma Initiative [NCT00987454]
Ask authors/readers for more resources
Erythropoietin (EPO) is a 30.4 kDa glycoprotein produced by the kidney, and is mostly well-known for its physiological function in regulating red blood cell production in the bone marrow. Accumulating evidence, however, suggests that EPO has additional organ protective effects, which may be useful in the prevention or treatment of acute kidney injury. These protective mechanisms are multifactorial in nature and include inhibition of apoptotic cell death, stimulation of cellular regeneration, inhibition of deleterious pathways, and promotion of recovery. In this article, we review the physiology of EPO, assess previous work that supports the role of EPO as a general tissue protective agent, and explain the mechanisms by which it may achieve this tissue protective effect. We then focus on experimental and clinical data that suggest that EPO has a kidney protective effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available